Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$244.48
-$0.55(-0.40%)
At close: 4:00 PM EST
$244.48
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$160.86 - $250.74
Previous CloseN/A
Volume129.18K
Average Volume (3M)617.50K
Market Cap
$14.40B
Enterprise Value$12.79B
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)24.5
Beta0.73
Next Earnings
Aug 06, 2026EPS Estimate
1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume600,517
30 Day Avg. Volume617,504
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue14.75
Enterprise Value/Gross Profit16.73
Enterprise Value/Ebitda1.03K
Forecast
1Y Price Target
$300.80Price Target Upside23.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)13.38
Revenue Forecast (FY)$1.33B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthSustained high gross margins (~88%) alongside recent double‑digit revenue growth create durable unit economics. This supports scalable operating leverage as commercial products expand, enabling margin expansion over 2–6 months if revenue retention and payer access remain stable.
Rapid Commercial Adoption Of Key ProductsStrong uptake — broadening prescriber base and rising new patient starts — indicates durable product-market fit in rare endocrine niches. Growing upstream coverage (~80%) and improving approval timing support repeatable sales growth and formulary access over upcoming quarters.
Improved Cash Generation And Balance Sheet ActionsMaterial improvement in operating and free cash flow, plus a large PRV inflow and redemption of convertible notes, enhance near‑term liquidity and reduce refinancing risk. This strengthens the company’s ability to fund commercialization and prioritized R&D without immediate external financing.
Bears Say
Meaningful Leverage & Prior Negative EquityElevated debt relative to equity and a recent history of negative equity constrain financial flexibility. If operating performance falters or growth slows, interest and principal obligations could force cost cuts, asset sales, or dilutive financing, limiting strategic optionality over the medium term.
Earnings Quality & Operating Profitability ConcernsA GAAP net income swing driven by nonrecurring tax recognition and only modest operating cash conversion highlights fragility in core profitability. Sustainable earnings depend on converting non‑IFRS gains into recurring operating cash, otherwise reported profits may prove transient.
Regulatory/legal, Supply Uncertainty And Narrower PipelineLegal and supply uncertainties around a newly launched product can constrain commercial scale and delay revenues. Simultaneously exiting internal oncology reduces diversification of future growth drivers, concentrating commercial and clinical risk into the endocrinology franchise.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $160.86 and its highest was $250.74 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $14.40B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on May 07, 2026. The company reported $11.251 earnings per share for the quarter, beating the consensus estimate of $0.187 by $11.064.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is 1.74.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 62,376,846 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of $11.251 in its last earnings report, beating expectations of $0.187. Following the earnings report the stock price went up 4.341%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$300.80 (23.04% Upside)
$300.80 (23.04% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 302.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.21%
12-Months-Change
Fundamentals
Return on Equity
-5641.90%
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$300.80
▲(23.04% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
<0.01% Insiders
11.59% Mutual Funds
― Other Institutional Investors
86.20% Public Companies and
Individual Investors